Department of Chemistry and Department of Medicinal Chemistry, Purdue University, West Lafayette, IN 47907, USA.
Departments of Biology and Chemistry, Molecular Basis of Disease, Georgia State University, Atlanta, GA 30303, USA.
ChemMedChem. 2022 May 4;17(9):e202200058. doi: 10.1002/cmdc.202200058. Epub 2022 Mar 4.
The design, synthesis, X-ray structural, and biological evaluation of a series of highly potent HIV-1 protease inhibitors are reported herein. These inhibitors incorporate novel cyclohexane-fused tricyclic bis-tetrahydrofuran as P2 ligands in combination with a variety of P1 and P2' ligands. The inhibitor with a difluoromethylphenyl P1 ligand and a cyclopropylaminobenzothiazole P2' ligand exhibited the most potent antiviral activity. Also, it maintained potent antiviral activity against a panel of highly multidrug-resistant HIV-1 variants. The corresponding inhibitor with an enantiomeric ligand was significantly less potent in these antiviral assays. The new P2 ligands were synthesized in optically active form using enzymatic desymmetrization of meso-diols as the key step. To obtain molecular insight, two high-resolution X-ray structures of inhibitor-bound HIV-1 protease were determined and structural analyses have been highlighted.
本文报道了一系列高效抗 HIV-1 蛋白酶抑制剂的设计、合成、X 射线结构和生物学评价。这些抑制剂将新型环己烷稠合三环双四氢呋喃作为 P2 配体与各种 P1 和 P2'配体结合。具有二氟甲基苯 P1 配体和环丙基氨基苯并噻唑 P2'配体的抑制剂表现出最强的抗病毒活性。此外,它对一系列高度多药耐药的 HIV-1 变异体仍保持有效的抗病毒活性。在这些抗病毒测定中,具有对映体配体的相应抑制剂的活性显著降低。新的 P2 配体通过使用酶促不对称分解 meso-二醇作为关键步骤以光学活性形式合成。为了获得分子见解,确定了两个与抑制剂结合的 HIV-1 蛋白酶的高分辨率 X 射线结构,并强调了结构分析。